Oragenics, Inc.
New York Stock Exchange AmericanTotal Valuation
Oragenics, Inc. carries a market capitalization of 2.65M, placing it among publicly traded companies globally. Its enterprise value stands at -4.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.65M |
| Enterprise Value | -4.82M |
Share Statistics
Oragenics, Inc. currently has 4.38M shares outstanding.
| Shares Outstanding | 4.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.20 |
| P/FCF Ratio | -0.13 |
| P/OCF Ratio | -0.13 |
Financial Position
Oragenics, Inc. maintains a current ratio of 5.73, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.91, indicating moderate leverage, while an interest coverage ratio of -16.24 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.73 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -16.24 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -173.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -22,625.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Oragenics, Inc.'s stock has declined approximately -86.68481% over the past 52 weeks. The 50-day moving average sits at 0.61, while the 200-day moving average is 0.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | -86.68481% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 0.91 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.59M, while operating income came in at -9.59M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.59M |
| Pretax Income | -9.99M |
| Net Income | -9.83M |
| EBITDA | -9.59M |
| EBIT | -9.59M |
| Earnings Per Share (EPS) | -4.47 |
Balance Sheet
Oragenics, Inc. holds 6.11M in cash and equivalents against 56,134.00 in total debt, resulting in a net debt position of -6.05M. Total book value stands at -228.83M, with working capital of 6.18M providing operational flexibility.
| Cash & Cash Equivalents | 6.11M |
| Total Debt | 56,134.00 |
| Net Debt | -6.05M |
| Equity (Book Value) | -228.83M |
| Book Value Per Share | -104.11 |
| Working Capital | 6.18M |
Cash Flow
Oragenics, Inc. produced -9.33M in operating cash flow over the past twelve months.
| Operating Cash Flow | -9.33M |
| Capital Expenditures | N/A |
| Free Cash Flow | -9.33M |
| FCF Per Share | -4.25 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -976.48 |
| FCF Yield | -758.29 |
Stock Splits
Oragenics, Inc.'s most recent stock split took place on June 3, 2025 with a 30:1 split ratio.
| Last Split Date | 6/3/2025 |
| Split Ratio | 30:1 |
Scores
Oragenics, Inc. posts an Altman Z-Score of -45.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -45.45 |